AMO Pharma is a biopharmaceutical company incorporated in February of 2015. The co-founder, Dr. Michael Snape, has extensive experience in senior scientific and operational roles in both large pharma and biotech companies spanning more than twenty-five years, and has brought together a targeted and experienced senior management team with a proven track record of success in all phases of product development and acquisition. The company is working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare, debilitating childhood onset neurogenetic disorders with limited or no treatment options. AMO-02 is an investigational medicine that has not yet been approved for the treatment of patients anywhere in the world. For more information, please visit the AMO Pharma website at http://www.amo-pharma.com/.
Looking for a particular AMO Pharma LTD employee's phone or email?
The AMO Pharma LTD annual revenue was $17 million in 2026.
Alan Rubino is the Executive Chairman of the Board of AMO Pharma LTD.
4 people are employed at AMO Pharma LTD.
AMO Pharma LTD is based in Durham, North Carolina.
The NAICS codes for AMO Pharma LTD are [3254, 32, 32541, 325].
The SIC codes for AMO Pharma LTD are [283, 28].